Author + information
- Myrthe E. Menting, MD,
- Judith A.A.E. Cuypers, MD and
- Jolien W. Roos-Hesselink, MD, PhD∗ ()
- ↵∗Erasmus University Medical Center, Department of Cardiology, Room Ba-583a, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands
We thank Dr. Marmoush and colleagues for their response to our paper (1) describing the survival and clinical outcome in patients up to 40 years after surgical closure of a ventricular septal defect (VSD).
Dr. Marmoush and colleagues justly remarked the high incidence of VSD in infants with Down syndrome. Patients with Down syndrome have a shorter life expectancy than the general population (2). In our study, we used survival rates of an age-matched Dutch population, which were on the basis of all Dutch residents, including patients with Down syndrome. In the 1980s, the estimated incidence of Down syndrome among newborns in the Netherlands was 10 to 14 per 10,000 live births (3). In our study cohort consisting of 174 patients with VSD, none had Down syndrome, even though Down syndrome was not an exclusion criterion. This could probably be explained by the fact that in this early surgical era heart defects were not always surgically repaired in patients with Down syndrome and by the relatively small number of included patients. Therefore, we think that, regarding the prevalence of Down syndrome, it was justified to compare the survival rates of our study cohort with those of the normal Dutch population. However, 8 patients with other syndromic, chromosomal, or psychomotor abnormalities participated in our study: psychomotor retardation (n = 3), 22q11 deletion (n = 2 of whom 1 deceased), VACTERL (Vertebral anomalies, Anal atresia, Cardiac defects, Tracheoesophageal fistula and/or Esophageal atresia, Renal & Radial anomalies and Limb defects) association (n = 1), Holt-Oram syndrome (n = 1), and hereditary motor and sensory neuropathy (n = 1). The mortality in this subgroup of patients with a syndrome is comparable with the mortality in our complete cohort (i.e., 31 deceased patients out of the 156 traceable patients). In conclusion, we agree that syndromic or chromosomal abnormalities can affect survival rates in general, but this does not affect the results in our study.
Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- 2015 American College of Cardiology Foundation
- Menting M.E.,
- Cuypers J.A.,
- Opic P.,
- et al.
- De Walle H.E.,
- Cornel M.C.